LLY Sep 2023 420.000 call
| Previous close | 32.55 |
| Open | 39.80 |
| Bid | 39.05 |
| Ask | 41.30 |
| Strike | 420.00 |
| Expiry date | 2023-09-15 |
| Day's range | 39.80 - 39.80 |
| Contract range | N/A |
| Volume | |
| Open interest | 359 |
ReutersNovartis drug cuts recurrence risk by 25% in early-stage breast cancer
Novartis breast cancer drug Kisqali cut the risk of recurrence by more than 25% in a pivotal trial on women diagnosed at an early stage, positioning the Swiss drugmaker to win new patients and but facing strong competition from Eli Lilly. The company on Friday said the relative risk reduction of cancer recurrence was 25.2% and that the results were broadly consistent regardless of patients' menopausal status or cancer progression status. The results were presented at the annual meeting of the American Society of Clinical Oncology in Chicago.
ZacksEli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
ZacksZacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novo Nordisk, Roche and Novartis
Eli Lilly, Johnson & Johnson, Novo Nordisk, Roche and Novartis have been highlighted in this Industry Outlook article.
Zacks5 Large Drug Stocks to Watch From a Thriving Industry
Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Roche (RHHBY) and Novartis (NVS) are worth retaining in your portfolio.
Motley Fool2 Newly Minted AI Stocks to Buy Right Now
Nowhere is this trend more evident than in the recent parabolic growth of graphics, computing, and networking solutions company Nvidia (NASDAQ: NVDA). Thanks to its central role as a pillar of global AI architecture, Nvidia has seen its market cap swell to nearly $1 trillion in 2023.
Motley FoolBetter Dividend Stock: Eli Lilly or Novo Nordisk?
Dividend stocks, on balance, tend to deliver market-beating returns on capital over the long haul. The key reason is that regular dividend payments amplify returns through the power of compounding. Selecting dividend stocks is no easy task, however.
- Financial Times
No ‘magic wand’ for financial pressures, Hunt tells pharma groups
UK chancellor Jeremy Hunt has told drugmakers that the government has no “magic wand” to deal with financial pressures and was unlikely to give into industry demands to pay a significantly higher price for medicines. The government will on Friday unveil reforms worth £650mn to boost the life sciences sector as part of a wider package of measures. Drugmakers have condemned the government for this year increasing a tax on sales of drugs to the NHS to 26.5 per cent, from 5.1 per cent over the past two years.
ZacksPfizer's (PFE) Oral Diabetes Drug Aids in Weight Loss, Stock Up
Data from a phase II study published in JAMA showed that Pfizer's (PFE) danuglipron reduces glycated hemoglobin and fasting plasma glucose (at all doses) and body weight (at the highest doses) at week 16.
Motley Fool1 Major Advantage Biogen May Have Over Pharma Giant Eli Lilly in a Multibillion-Dollar Market
Analysts are bullish on Biogen's Alzheimer's drug, Leqembi, projecting it may generate over $10 billion in sales at its peak.
ZacksInvestors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
ZacksEli Lilly (LLY) Stock Up 18.7% YTD, New Drugs Key to Growth
Lilly (LLY) expects to launch four new medicines by 2023 end, of which Mounjaro for type II diabetes and cancer drug Jaypirca have already been launched.
Motley FoolThese 2 Pharma Stocks Might Face Off Soon -- but They Could Both Win
Eli Lilly (NYSE: LLY) and Biogen (NASDAQ: BIIB) are both keen to compete in the market for Alzheimer's disease therapies. Biogen's prior attempt at an Alzheimer's medicine to hit the market was a train wreck, but its latest drug seems to be avoiding a repeat. Meanwhile, Eli Lilly has yet to submit its candidate for regulatory review.
Motley Fool3 Growth Stocks to Buy and Hold
The stock market's short-term volatility can sometimes cloud investors' judgment and cause panic selling. In that spirit, we asked three Motley Fool contributors to discuss buy-and-hold-worthy growth stocks. Read on to find out why they picked Axsome Therapeutics (NASDAQ: AXSM), Eli Lilly (NYSE: LLY), and Vertex Pharmaceuticals (NASDAQ: VRTX).
Motley FoolWill Eli Lilly Be a Trillion-Dollar Stock by 2030?
Most investors are comfortable with the idea of businesses like Apple and Microsoft having market caps in excess of $1 trillion. Today, Eli Lilly's market cap is a little north of $410 billion, which puts it among the top handful of big pharma companies. Its trailing 12-month net income is $6.2 billion, and its trailing price-to-earnings ratio is near 69, which is fairly high, but not at bloated tech stock levels.
Motley FoolHere’s What Eli Lilly’s Latest Clinical Win Means For Investors
Few pharmaceutical giants have performed as well or better than Eli Lilly (NYSE: LLY) in the stock market over the past year. The Indianapolis-based company's secret wasn't its financial results, as they were relatively mild, or even downright disappointing, for much of this period. The market is forward-looking, and with the drugmaker producing several highly promising programs, investors are increasingly excited regarding Eli Lilly's future.
Motley FoolHere's Why Eli Lilly's Alzheimer's Drug Could Be the Real Deal
Eli Lilly stock may look expensive, but there's still plenty of value here for long-term investors.
ZacksBearish Headwinds Have Evolved to Bullish Tailwinds: This Industry Soars
The headline inflation figure rose at the slowest rate in more than two years.
ZacksNektar Therapeutics (NKTR) Q1 Earnings & Revenues Beat
Nektar's (NKTR) Q1 loss is narrower than expected while revenues beat estimates.
ZacksThe Zacks Analyst Blog Highlights Eli Lilly, Verizon Communications, United Parcel Service, Advanced Micro Devices and The Cigna Group
Eli Lilly, Verizon Communications, United Parcel Service, Advanced Micro Devices and The Cigna Group are part of the Zacks Analyst Blog.
ZacksTop Stock Reports for Eli Lilly, Verizon Communications & United Parcel Service
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Verizon Communications Inc. (VZ) and United Parcel Service, Inc. (UPS).
ZacksPharma ETFs Gain Post Q1 Earnings
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. As such, pharma ETFs have been in the green over the past month.
Motley FoolWhy Did Eli Lilly Stock Jump 15% in April?
Shares of Eli Lilly (NYSE: LLY) climbed 15.3% last month, according to S&P Global Market Intelligence. Promising drug trial developments and a strong outlook from management in its first-quarter report provided the upward momentum to the pharmaceutical stock. Eli Lilly caught Wall Street's attention early in April after announcing positive results from an early clinical trial for an experimental Alzheimer's drug.
Motley FoolWhere Will Eli Lilly Be in 3 Years?
The pharmaceutical giant is likely to grow quickly as it is entering a new age of contested markets.
Motley Fool3 Things About Eli Lilly That Smart Investors Know
Eli Lilly (NYSE: LLY) is getting a lot of Wall Street attention again. Eli Lilly's drug development pipeline is as big as they come, and that means plenty of new medicines are likely to hit the market in any given period. Within the next year, Lilly could commercialize tirzepatide for obesity, donanemab for Alzheimer's disease, empagliflozin for chronic kidney disease, and lebrikizumab for atopic dermatitis.
Motley Fool2 Top Healthcare Stocks Defying the Bear Market
Eli Lilly (NYSE: LLY) and Merck (NYSE: MRK) have seen their shares rise by over 17% and 5%, respectively, this year while the S&P 500 Health Care Sector Index has dropped 1.7%. For Merck, it is a pipeline bolstered by vaccines and oncology therapies. For Lilly, it's a weight-loss drug and an Alzheimer's disease therapy that are showing huge potential.
